瑞典Pfizer/BioNTech实战有效性，一针 42%，二针7天内只有60%，二针7天后 86%， 以前感染过的人打了疫苗91%有效。

[billwanhua]

How effective is the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine? A real-world study in Sweden

Investigating a population in southern Sweden, a new study has found that a single dose of the vaccine is only about 42% effective in preventing coronavirus disease 2019 (COVID-19). But seven days after the second dose, the vaccine can prevent COVID-19 in 86% of the population.

www.news-medical.net

Of the total of 805,741 study participants, about 3% had been vaccinated by the BNT16b2 mRNA vaccine by 28 February 2021. About 80% of the vaccinated individuals were women, and the median age of the vaccinated set of people was 47 years.

Two weeks after the first dose, the vaccine was only about 42% effective. But it was 86% effective in preventing COVID-19 in people who had no prior infection seven days after the second dose for the period 15-28 February 2021. There was no difference in vaccine effectiveness between males and females.

he study found lower vaccine effectiveness of about 60% within seven days of the second dose.

People who had been infected before showed a 91% vaccine effectiveness. The effectiveness was still high when people had been infected more than three months before vaccination.

打了一针疫苗的还是不能浪。第二针7天内只有60%

 

[向问天]

​

​

以前感染过的人打了疫苗91%有效。这个也是两针之后的有效率吧？​

 

[向问天]

科兴疫苗对应的真实世界数据

China's Sinovac COVID-19 vaccine was 67% effective in preventing symptomatic infection, data from a huge real-world study inChile has shown, a potential boost for the jab which has come under scrutiny over its level of protection against the virus.

The CoronaVac vaccine was 85% effective in preventing hospitalizations and 80% effective in preventing deaths, the Chilean government said in a report, adding that the data should prove a "game changer" from the vaccine more widely.

China’s Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection - Chile govt report

China's Sinovac COVID-19 vaccine was 67% effective in preventing symptomatic infection, data from a huge real-world study inChile has shown, a potential boost for the jab which has come under scrutiny over its level of protection against the virus.

www.reuters.com

 

[billwanhua]

英国实战研究，辉瑞疫苗对于老年人（aged 80 to 83 years)处于英国变异高发区的英国的有效率：

Pfizer-BioNTech COVID-19 vaccine shows real-world efficacy, despite the circulation of B.1.1.7 variant

Researchers in the UK have conducted a study showing the real-world effectiveness of Pfizer-BioNTech’s vaccine at protecting against symptomatic coronavirus disease 2019 (COVID-19) when it is administered in line with the original dosing schedule.

www.news-medical.net

The vaccine’s efficacy against SARS-CoV-2 infection was estimated to be around 55% after one dose and approximately 70% after a second dose administered 21 days later.

The team matched 170,226 vaccine recipients (aged 80 to 83 years) from the community setting outside of care homes with slightly younger (aged 76-79 years) individuals not yet eligible for vaccination on gender, area of residence, health status, living arrangements, acute illness, and history of seasonal flu vaccination.

这个实验对照组（80-83岁）打了疫苗和（76-79岁）没有打疫苗的人。虽然不是严格的同年龄实验，但是也差不多。

The rates of emergency hospital admissions and infection were 51.0% and 55.2% lower, respectively, for vaccinated individuals versus matched controls at 21 to 27 days following first vaccination.

The rates of emergency admissions and infections were 75.6% and 70.1% lower 35 to 41 days following first vaccination when 80% of participants had received their second dose.

 

[向问天]

英国实战研究，辉瑞疫苗对于老年人（aged 80 to 83 years)处于英国变异高发区的英国的有效率：

Pfizer-BioNTech COVID-19 vaccine shows real-world efficacy, despite the circulation of B.1.1.7 variant

Researchers in the UK have conducted a study showing the real-world effectiveness of Pfizer-BioNTech’s vaccine at protecting against symptomatic coronavirus disease 2019 (COVID-19) when it is administered in line with the original dosing schedule.

www.news-medical.net

The vaccine’s efficacy against SARS-CoV-2 infection was estimated to be around 55% after one dose and approximately 70% after a second dose administered 21 days later.

The team matched 170,226 vaccine recipients (aged 80 to 83 years) from the community setting outside of care homes with slightly younger (aged 76-79 years) individuals not yet eligible for vaccination on gender, area of residence, health status, living arrangements, acute illness, and history of seasonal flu vaccination.

这个实验对照组（80-83岁）打了疫苗和（76-79岁）没有打疫苗的人。虽然不是严格的同年龄实验，但是也差不多。

The rates of emergency hospital admissions and infection were 51.0% and 55.2% lower, respectively, for vaccinated individuals versus matched controls at 21 to 27 days following first vaccination.

The rates of emergency admissions and infections were 75.6% and 70.1% lower 35 to 41 days following first vaccination when 80% of participants had received their second dose.

看来是对越年轻的人越有效。

 

[向问天]

“以前感染过的人打了疫苗91%有效。”​

以前感染过的人，又再打疫苗，才91%有效。​

的确不能说好。

 

[billwanhua]

“以前感染过的人打了疫苗91%有效。”​

以前感染过的人，又再打疫苗，才91%有效。​

的确不能说好。

let us put it this way, there gonna be someones to be doomed from being saved.